Zealand Pharma Beheer

Beheer criteriumcontroles 3/4

De CEO Zealand Pharma is Adam Steensberg, benoemd in Mar2022, heeft een ambtstermijn van 2.67 jaar. De totale jaarlijkse vergoeding van { bedraagt DKK 24.84M, bestaande uit 23.2% salaris en 76.8% bonussen, inclusief aandelen en opties van het bedrijf. bezit rechtstreeks 0.048% van de aandelen van het bedrijf, ter waarde DKK 23.01M. De gemiddelde ambtstermijn van het managementteam en de raad van bestuur bedraagt respectievelijk 3.2 jaar en 9.6 jaar.

Belangrijke informatie

Adam Steensberg

Algemeen directeur

DKK 24.8m

Totale compensatie

Percentage CEO-salaris	23.2%
Dienstverband CEO	2.7yrs
Eigendom CEO	0.05%
Management gemiddelde ambtstermijn	3.2yrs
Gemiddelde ambtstermijn bestuur	9.6yrs

Recente managementupdates

Recent updates

Zealand Pharma A/S (CPH:ZEAL) Just Released Its Second-Quarter Earnings: Here's What Analysts Think

Aug 18

Auditors Are Concerned About Zealand Pharma (CPH:ZEAL)

Mar 17

Here's Why We're Watching Zealand Pharma's (CPH:ZEAL) Cash Burn Situation

Oct 03

Downgrade: Here's How Analysts See Zealand Pharma A/S (CPH:ZEAL) Performing In The Near Term

Aug 14

Analyse CEO-vergoeding

Hoe is Adam Steensberg's beloning veranderd ten opzichte van Zealand Pharma's winst?
Datum	Totale vergoeding	Salaris	Bedrijfswinsten
Sep 30 2024	n/a	n/a	-DKK 1b
Jun 30 2024	n/a	n/a	-DKK 712m
Mar 31 2024	n/a	n/a	-DKK 739m
Dec 31 2023	DKK 25m	DKK 6m	-DKK 704m
Sep 30 2023	n/a	n/a	-DKK 760m
Jun 30 2023	n/a	n/a	-DKK 986m
Mar 31 2023	n/a	n/a	-DKK 1b
Dec 31 2022	DKK 19m	DKK 4m	-DKK 966m
Sep 30 2022	n/a	n/a	-DKK 855m
Jun 30 2022	n/a	n/a	-DKK 845m
Mar 31 2022	n/a	n/a	-DKK 608m
Dec 31 2021	DKK 10m	DKK 3m	-DKK 755m
Sep 30 2021	n/a	n/a	-DKK 925m
Jun 30 2021	n/a	n/a	-DKK 1b
Mar 31 2021	n/a	n/a	-DKK 909m
Dec 31 2020	DKK 7m	DKK 3m	-DKK 669m
Sep 30 2020	n/a	n/a	-DKK 660m
Jun 30 2020	n/a	n/a	-DKK 545m
Mar 31 2020	n/a	n/a	-DKK 624m
Dec 31 2019	DKK 7m	DKK 3m	-DKK 572m

Compensatie versus markt: De totale vergoeding ($USD 3.51M ) Adam } is ongeveer het gemiddelde voor bedrijven van vergelijkbare omvang in de Danish markt ($USD 3.24M ).

Compensatie versus inkomsten: De vergoeding van Adam is gestegen terwijl het bedrijf verliesgevend is.

CEO

Adam Steensberg (50 yo)

2.7yrs

Tenure

DKK 24,837,000

Compensatie

Mr. Adam Sinding Steensberg, M.D., serves as President and Chief Executive Officer at Zealand Pharma A/S since March 30, 2022. He had been an Executive Vice President of Research & Development and Chief Me...

Leiderschapsteam

Naam	Positie	Tenure	Compensatie	Eigendom
Adam Steensberg	President & CEO	2.7yrs	DKK 24.84m	0.048% DKK 23.0m
Henriette Wennicke	EVP & CFO	2yrs	DKK 9.24m	0.0049% DKK 2.3m
Ivan Moller	Executive VP & COO	6.7yrs	geen gegevens	0.064% DKK 30.7m
David Kendall	Chief Medical Officer and Head of R&D	no data	geen gegevens	0.013% DKK 6.3m
Mads Kronborg	Head of Investor Relations & Communication	4.3yrs	geen gegevens	geen gegevens
Ravinder Chahil	EVP & General Counsel	2.8yrs	geen gegevens	0.010% DKK 5.0m
Christina Bredal	Executive VP & Chief People Officer	3.6yrs	geen gegevens	0.0095% DKK 4.6m
Jens Mikkelsen	Head of Molecular Pharmacology	no data	geen gegevens	geen gegevens
Danilo Verge	Head of Global Medical Affairs	4.2yrs	geen gegevens	geen gegevens
Lykke Romer	VP & Head of Finance and Accounting	no data	geen gegevens	geen gegevens
Eric Cox	Chief Commercial Officer	less than a year	geen gegevens	geen gegevens
Miriam Katz	Assistant Secretary	no data	geen gegevens	geen gegevens

3.2yrs

Gemiddelde duur

51yo

Gemiddelde leeftijd

Ervaren management: Het managementteam van ZEAL wordt beschouwd als ervaren (gemiddelde ambtstermijn 3.2 jaar).

Bestuursleden

Naam	Positie	Tenure	Compensatie	Eigendom
Leonard Kruimer	Independent Director	5.6yrs	DKK 764.00k	0.022% DKK 10.4m
Alf Gunnar Nicklasson	Independent Chairman of the Board	9.6yrs	DKK 1.07m	0.026% DKK 12.6m
Kirsten Drejer	Independent Vice Chairman	6.6yrs	DKK 583.00k	0.012% DKK 6.0m
Ake Lernmark	Member of Advisory Board	13yrs	geen gegevens	geen gegevens
Gudmund Korsgard	Board Observer	no data	geen gegevens	geen gegevens
Jeffrey Berkowitz	Independent Director	5.6yrs	DKK 583.00k	0.012% DKK 5.5m
Bernard Charbonnel	Member of Advisory Board	13yrs	geen gegevens	geen gegevens
Richard Pratley	Member of Advisory Board	13yrs	geen gegevens	geen gegevens
Paul Dorian	Member of Advisory Board	13yrs	geen gegevens	geen gegevens
Gert Van Assche	Member of Advisory Board	13yrs	geen gegevens	geen gegevens
Bernadette Connaughton	Independent Director	5.6yrs	DKK 583.00k	0.012% DKK 5.7m
Anneline Nansen	Employee Representative Director	3.2yrs	DKK 281.00k	0% DKK 0

9.6yrs

Gemiddelde duur

66.5yo

Gemiddelde leeftijd

Ervaren bestuur: De raad van bestuur van ZEAL wordt beschouwd als ervaren (gemiddelde ambtstermijn 9.6 jaar).

Zealand Pharma Beheer

Beheer criteriumcontroles 3/4

Belangrijke informatie

Recente managementupdates

Employee Representative Director recently sold kr.1.3m worth of stock

Insufficient new directors

President & CEO recently sold kr.31m worth of stock

Zealand Pharma A/S Appoints Eric Cox as Chief Commercial Officer, Effective August 5, 2024

Zealand Pharma A/S Approves Appointments to the Board

Zealand Pharma A/S Announces Board Changes

Recent updates

Employee Representative Director recently sold kr.1.3m worth of stock

Forecast to breakeven in 2025

Analyst Forecasts For Zealand Pharma A/S (CPH:ZEAL) Are Surging Higher

Third quarter 2024 earnings: EPS exceeds analyst expectations while revenues lag behind

Zealand Pharma A/S to Report Q1, 2025 Results on May 08, 2025

Consensus EPS estimates fall by 14%

Zealand Pharma Provides U.S. Regulatory Update on Dasiglucagon in Congenital Hyperinsulinism

Insufficient new directors

Rock star Growth Puts Zealand Pharma (CPH:ZEAL) In A Position To Use Debt

President & CEO recently sold kr.31m worth of stock

Consensus revenue estimates fall by 11%

Things Look Grim For Zealand Pharma A/S (CPH:ZEAL) After Today's Downgrade

Zealand Pharma A/S (CPH:ZEAL) Just Released Its Second-Quarter Earnings: Here's What Analysts Think

Second quarter 2024 earnings: Revenues exceed analysts expectations while EPS lags behind

Consensus EPS estimates fall by 40%

Zealand Pharma A/S Appoints Eric Cox as Chief Commercial Officer, Effective August 5, 2024

Zealand Pharma A/S has filed a Follow-on Equity Offering in the amount of DKK 6.257 billion.

Zealand Pharma A/S Announces Positive Topline Results from the Phase 1B 16-Week Multiple Ascending Dose Clinical Trial with Long-Acting Amylin Analog Petrelintide

Zealand Pharma A/S Announces Boehringer Ingelheim Will Present Positive Results from Phase 2 Trial with Survivalodutide in MASH at EASL

Zealand Pharma Announces Topline Results from the Mechanistic Investigator-Led Dream Trial with Low Doses of GLP-1/GLP-2 Receptor Dual Agonist Dapiglutide

Zealand Pharma A/S Approves Appointments to the Board

Zealand Pharma A/S Announces Board Changes

Zealand Pharma A/S Announces Boehringer Ingelheim Survodutide Phase 2 Trial Shows 83% of Adults Treated a Statistically Significant Improvement of Metabolic Dysfunction-Associated Steatohepatitis

Zealand Pharma A/S, Annual General Meeting, Mar 20, 2024

Zealand Pharma A/S has completed a Follow-on Equity Offering in the amount of DKK 1.45362 billion.

Zealand Pharma A/S has filed a Follow-on Equity Offering in the amount of DKK 1.45362 billion.

Zealand Pharma A/S Appoints Enrique Conterno and Elaine Sullivan as Board Observers

Zealand Pharma A/S to Report Q1, 2024 Results on May 16, 2024

Boehringer Ingelheim and Zealand Pharma A/S Announces Initiation of Three Phase III Trials

Zealand Pharma A/S Announces Designation of Priority Review by the US FDA for Dasiglucagon in Congital Hyperinsulinism

Zealand Pharma A/S Announces Positive Results from Part 1 of Multiple Ascending Dosing Trial with Amylin Analog ZP8396

Zealand Pharma Submits Marketing Authorization Application for Dasiglucagon for Treatment of Severe Hypoglycemia in Diabetes to the European Medicines Agency

Boehringer Ingelheim and Zealand Pharma A/S Announces Phase II Trial Showed 14.9% Weight Loss in People Living with Obesity or Unveil

Zealand Pharma A/S has completed a Follow-on Equity Offering in the amount of DKK 786.05 million.

Zealand Pharma A/S Announces Positive Results from Phase 3 Trial of Glepaglutide in Patients with Short Bowel Syndrome (Ease 1)

Zealand Pharma Presents Data from Phase 3 Trial of Dasiglucagon in Congenital Hyperinsulinism At the 60Th Annual Espe Meeting

Zealand Pharma A/S Announces Chief Financial Officer Changes

Zealand Pharma A/S Revises Revenue Guidance for the Full Year of 2022

Zealand Pharma Announces Voluntary Delisting of American Depositary Shares from the Nasdaq Global Select Market

Zealand Pharma A/S Presents Data from Phase 1 Trial of Dapiglutide and to Move into Phase 2 Trial for Obesity

Zealand Pharma Announces Appoints David M. Kendall, as Chief Medical Officer

Insufficient new directors

Consensus forecasts updated

Zealand Pharma A/S Announces Positive Top-Line Results from Its Second Phase 3 Clinical Trial of Dasiglucagon in Pediatric Patients with Congenital Hyperinsulinism

Zealand Pharma A/S (CPSE:ZEAL) entered into an agreement to acquire V-Go® Insulin Delivery Device from Zealand Pharma for $10 million.

First quarter 2022 earnings: EPS exceeds analyst expectations while revenues lag behind

Insufficient new directors

Price target decreased to kr.229

Zealand Pharma Announces CEO Changes

Auditors Are Concerned About Zealand Pharma (CPH:ZEAL)

Full year 2021 earnings: Revenues in line with analyst expectations

Consensus forecasts updated

Zealand Pharma A/S Announces Completion of Patient Enrollment in the Second Phase 3-Trial, 17103 in Children with Congenital Hyperinsulinism

Zealand Pharma Completes Enrollment in Ease-SBS 1 Phase 3 Trial Assessing Glepaglutide in Patients with Short Bowel Syndrome

Zealand Pharma Announces Enrollment of Last Patient Needed for Interim Analysis of EASE-SBS 1 Phase 3 Trial Assessing Glepaglutide in Patients with Short Bowel Syndrome

Consensus forecasts updated

Zealand Pharma A/S announced that it expects to receive $200 million in funding from Oberland Capital Management LLC

Zealand Pharma Announces Successful Outcome of Phase 1B Clinical Trial with GLP1-GLP2 Dual Receptor Agonist, Dapiglutide

Price target decreased to kr.228

Third quarter 2021 earnings released: kr.4.61 loss per share (vs kr.5.76 loss in 3Q 2020)

Price target decreased to kr.236

Here's Why We're Watching Zealand Pharma's (CPH:ZEAL) Cash Burn Situation

Zealand Pharma A/S Presents Data At 2021 ESPEN Virtual Congress Demonstrating Dose-Dependent Effects of Glepaglutide in Both Small and Large Intestines of Animal Models –in Contrast to Short-Acting GLP-2

Employee Elected Director Gertrud Rasmussen has left the company

Employee Elected Director Gertrud Rasmussen has left the company

Zealand Pharma Announces First Patient Dosed in EASE-SBS 4 Phase 3b Trial Assessing Glepaglutide in Patients with Short Bowel Syndrome

Downgrade: Here's How Analysts See Zealand Pharma A/S (CPH:ZEAL) Performing In The Near Term

Consensus EPS estimates fall to -kr.28.75

Protagonist Therapeutics, Inc Announces Resolution of Contract Dispute with Zealand Pharma